| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc. | ASC40 (denifanstat) | Moderate to severe acne | Phase 3 | Data Released | oral | N/A |
| Sagimet Biosciences Inc. | Denifanstat - (FASCINATE-3) | Nonalcoholic steatohepatitis (NASH) | Phase 2b | Data Released | Oral | Gastroenterology |
| Sangamo Therapeutics Inc. | Civaparvovec (ST-920) - (STAAR) | Fabry disease | BLA Filing | Data Released | Intravenous | Genetic Disorder |
| Sangamo Therapeutics Inc. | Giroctocogene fitelparvovec (SB-525) - (AFFINE) | Hemophilia A | BLA Filing | Withdrawn | Intravenous | Hematology |
| Sanofi | Venglustat | Tay-Sachs disease / GM-2 gangliosidoses | NDA Filing | Ongoing | Oral | Genetic Disorder |
| Sanofi | LIBTAYO (cemiplimab) | Cervical cancer | NDA Filing | Withdrawn | intravenous | Oncology |
| Sanofi | LIBTAYO (cemiplimab) | Cervical cancer | NDA Filing | Withdrawn | intravenous | Oncology |
| Sanofi | Venglustat | Tay-Sachs disease / GM-2 gangliosidoses | NDA Filing | Ongoing | Oral | Genetic Disorder |